Navigation Links
Amylin Pharmaceuticals Reports First Quarter Financial Results
Date:4/21/2008

or $0.38 per share, for the same period in 2007.

First Quarter 2008 Highlights

Highlights of Amylin's first quarter include:

BYETTA

-- Submitted a supplemental New Drug Application, or sNDA, to the Food and

Drug Administration, or FDA, to seek approval for expanded use of

BYETTA as monotherapy, or stand-alone therapy, in people with type 2

diabetes who are not achieving acceptable blood sugar control.

Approval for this expanded indication is expected in the second

half of 2008.

SYMLIN

-- Commercially launched the SymlinPen(TM) 120 and the SymlinPen(TM) 60

pen-injector devices for administering SYMLIN in the United States in

January 2008. These new pre-filled pen-injector devices feature

simple, fixed dosing to improve mealtime glucose control.

Exenatide once weekly

-- Initiated the first of three planned superiority clinical trials of

exenatide once weekly. The study compares exenatide once weekly to a

thiazolidinedione, or TZD, and a DPP-4 inhibitor in patients on

background metformin therapy. Results from this study are expected in

the first half of 2009.

-- Continued progress at the Company's exenatide once weekly manufacturing

facility in Ohio, including the manufacture of exenatide once weekly at

commercial scale. The Company plans to supply material from the

facility to support ongoing and planned clinical programs by the third

quarter of 2008

Conference Call

Amylin will webcast its Quarterly Update Conference Call today at 8:30 a.m. ET/5:30 a.m. PT. The call will be webcast live through Amylin's corporate website, http://www.amylin.com, and a recording will be made available following the close of the call.

Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
6. Amylin Pharmaceuticals Reports 2007 Financial Results
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... How well patients recover from cancer surgery may ... and the operations themselves. Family conflicts and other ... complications, a Mayo Clinic study has found. Addressing ... patients, stress, speed their recoveries and save health ... looked at colon cancer patients, and found that ...
(Date:9/2/2014)... suggests that the key to more youthful immune function ... report published in the Journal of Leukocyte ... lungs of old mice had different responses to ... these changes were reversed by ibuprofen. , "Inflammation in ... said Joanne Turner, Ph.D., a researcher involved in the ...
(Date:9/2/2014)... 02, 2014 According to a ... the leading global authority in medical device market ... is expected to grow to over €2 billion ... increase in the number of procedures for the ... This market includes TURP devices, laser BPH devices, ...
(Date:9/2/2014)... 02, 2014 Nanomedicine is essentially ... diagnosing, treating and/or prevention of diseases and infections. ... cardiovascular, neurological, and oncology diseases. , Nanomedicine ... to various nanoparticles, their medical usages, and their ... considerable scope for research in this domain, and ...
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present ... vida! Get Up! Get Moving!®. This event promotes Hispanic family ... for people of all ages and all sizes. The event, ... held at Kiest Park Recreation Center, 3080 S. Hampton Road, ... “Since 2007, we have partnered with National Alliance for Hispanic ...
Breaking Medicine News(10 mins):Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
... Will Continue to be Used in Early ... from Decision Resources, WALTHAM, Mass., Oct. ... leading research and advisory firms focusing on ... is currently the leading biologic for Crohn,s ...
... 1, 2008 at this year,s liver ... SAN FRANCISCO, Oct. 27 Researchers analyzed 43,497,patients ... 22,863 adults,who received transplantation to determine the best time ... caused by differences in donor type was vastly offset ...
... 27 ReachMD XM 157 announces a new,"Medical ... receptor,antagonist and its effects on management of euvolemic ... XM 157, the first and only network for ... the Tide Against,Hyponatremia" four times a day October ...
... NORWALK, Conn., Oct. 27 Maclaren USA Inc.,announces the ... Chief Operation Officer., "Maclaren,s growth has been extraordinary ... our new from-birth transport system, the Grand Tour(TM),LX, is ... proven themselves to be exceptional leaders in their field. ...
... has donated a portable Automatic External Defibrillator (AED) to Habitat ... ... Newtown, Pennsylvania (PRWEB) October 27, 2008 -- HeartSine Technologies, ... donated a portable Automatic External Defibrillator (AED) to Habitat for ...
... reduced inflammation, cholesterol and belly fat , , SUNDAY, Oct. ... diet." , New research ties eating tart cherries ... weight and fat -- all major risk factors for ... presented by University of Michigan researchers at the American ...
Cached Medicine News:Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 2Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 3Health News:Early Liver Transplantation Regardless of Donor Type Increases Long-term Survival 2Health News:ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia 2Health News:ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia 3Health News:Maclaren Appoints New President and New Chief Operation Officer 2Health News:HeartSine Portable Defibrillator Donation Brings Added Safety to Habitat for Humanity of Charlotte ReStore Location 2Health News:Cherry-Enriched Diet Cut Heart Risks in Rats 2
(Date:9/2/2014)...  Volcano Corporation (Nasdaq: VOLC ), ... economic outcomes on a global basis by developing ... visualization, physiology diagnostics and therapies, said today that ... Healthcare conference on Tuesday, September 9. ... and chief executive officer, will begin at 11:10 ...
(Date:9/2/2014)... , Sept. 2, 2014  VentiRx Pharmaceuticals, ... to the development and commercialization of novel ... an update on corporate and clinical activities ... for future funding, ongoing clinical trials and ... In corporate news, Chief Executive Officer Robert ...
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced that the U.S. Food and ... designation to the investigation of motolimod (VTX-2337) ... doxorubicin (PLD) for the treatment of women ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 2VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer 3
... 5, 2011 Reportlinker.com announces that ... available in its catalogue: ... Cosmetic Surgery, Facial Aesthetic and Medical ... http://www.reportlinker.com/p0610527/Emerging-Markets-Chinese-and-Indian-Cosmetic-Surgery-Facial-Aesthetic-and-Medical-Laser-Markets-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply The ...
... 2011 The Board of Directors of MSA (NYSE: ... a Vice President of the company, responsible for Global Product ... of November 1, will assume the role of President of ... (MEZ).  In his new role, Dr. Muschter will become a ...
Cached Medicine Technology:Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 2Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 3Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 4Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 5Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 6Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 7Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 8Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 9Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 10Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 11Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 12Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 13Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 14Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 15Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 16Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 17Emerging Markets: Chinese and Indian Cosmetic Surgery, Facial Aesthetic and Medical Laser Markets 2011 18MSA Elects Dr. Thomas Muschter to Vice President 2
... KIMBERLY-CLARK BALLARD Adult TRACH ... in T-Piece, Elbow and Double ... separate from vials; 12 vials ... Offers multiple tracheostomy sizes, French ...
... KIMBERLY-CLARK BALLARD Adult TRACH ... designed and labeled for ... Features an isolated cleaning ... minimize potential for contamination ...
... Maxi-Flo® suction catheters ... or straight. , ... catheter kits are latex-free., ... feature a catheter tip ...
... are available with a single lumen or ... swivel, MDI adapter., ,Trac-Wedge™ device, and ... include a patient label. Dual swivel elbow ... All Portex® Steri-Cath® systems are latex-free. , ...
Medicine Products: